Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Zeshaan A. Rasheed

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-4143-5800; OpenAlex author ID A5112255519. Sources: funder_awards.

Their work

Papers
16 (first author 2, last author 1)
Trials
0
Grants
1
Labs led
0
Collaborators
63
Papers, trials and grants by year

2010: 1 grant · 2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 16

  1. Reversible chemoresistance of pancreatic cancer grown as spheroids. Co-author DOI 10.1080/1120009x.2024.2402177↗
  2. SREBP-Dependent Regulation of Lipid Homeostasis Is Required for Progression and Growth of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-24-0120↗
  3. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  4. Direct Interactions With Cancer-Associated Fibroblasts Lead to Enhanced Pancreatic Cancer Stem Cell Function. Co-author DOI 10.1097/mpa.0000000000001249↗
  5. Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-18-0367↗
  6. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcin… Co-author DOI 10.1158/1078-0432.ccr-16-1467↗
  7. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0180181↗
  8. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗
  9. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000001600↗
  10. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.09.050↗
  11. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.01.054↗
  12. Stem cell-directed therapies in pancreatic cancer. Last author DOI 10.1016/j.currproblcancer.2013.10.005↗
  13. Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. Co-author DOI 10.1111/j.1440-1746.2011.07015.x↗
  14. Heterogeneity and targeting of pancreatic cancer stem cells. First author DOI 10.1158/1078-0432.ccr-11-3112↗
  15. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. First author DOI 10.1158/1535-7163.mct-12-0017↗
  16. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Co-author DOI 10.4161/cbt.12.7.16475↗

Grants 1

  1. Are Cancer Stem Cells Relevant in Pancreatic Adenocarcinoma? AWARD pancan:2010-zeshaan-rasheed-md-phd-are-cancer-stem-cells-relevant-in-pancre

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asma Begum · 5 shared papers, 2017–2025 · strength 0.52
  2. Christopher Lee Wolfgang · 6 shared papers, 2016–2025 · strength 0.51
  3. Anirban Maitra · 9 shared papers, 2011–2020 · strength 0.48
  4. William H. Matsui · 8 shared papers, 2011–2019 · strength 0.42
  5. Michael Goggins · 4 shared papers, 2016–2025 · strength 0.41
  6. Robert A. Anders · 4 shared papers, 2016–2024 · strength 0.41
  7. N.V. Rajeshkumar · 6 shared papers, 2011–2020 · strength 0.31
  8. Ralph H. Hruban MD · 3 shared papers, 2016–2025 · strength 0.30
  9. Vesselin R. Penchev · 4 shared papers, 2012–2019 · strength 0.27
  10. Daniel A. Laheru · 4 shared papers, 2016–2020 · strength 0.23
  11. Yoshihisa Matsushita · 1 shared paper, 2025 · strength 0.21
  12. Alexis L. Norris · 1 shared paper, 2025 · strength 0.21
  13. Yi Zhong · 1 shared paper, 2025 · strength 0.21
  14. James R. Eshleman · 1 shared paper, 2025 · strength 0.21
  15. Peter J. Espenshade · 1 shared paper, 2024 · strength 0.19
  16. Hao Wang · 1 shared paper, 2024 · strength 0.19
  17. Casie S. Kubota · 1 shared paper, 2024 · strength 0.19
  18. Chiaki T. Ishida · 1 shared paper, 2024 · strength 0.19
  19. Ana De Jesus‐Acosta · 3 shared papers, 2016–2020 · strength 0.19
  20. Lei Zheng · 3 shared papers, 2016–2020 · strength 0.18
  21. Laura DeLong Wood · 3 shared papers, 2016–2017 · strength 0.17
  22. Amanda L. Blackford · 3 shared papers, 2016–2017 · strength 0.16
  23. Shinichi Yabuuchi · 3 shared papers, 2012–2020 · strength 0.15
  24. Roeland F. de Wilde · 3 shared papers, 2012–2020 · strength 0.15
  25. Florencia M. McAllister · 2 shared papers, 2014–2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.